Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

Expert Ratings For Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

3 Worst Performing Stocks in the S&P 500 Year-to-Date

S&P 500 stocks have been plummeting amid concerns about tighter monetary policy and the escalating war between Russia and Ukraine. This has triggered further selloffs, causing renowned stocks PayPal (PYPL), Moderna (MRNA), and EPAM Systems (EPAM) to lose momentum lately. Let’s discuss.

StockNews.com

Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Drugmakers Reap Billions Meeting Covid-19 Needs

Healthcare companies that came up with effective Covid-19 vaccines, treatments and tests are seeing a huge financial payoff and are starting to spend their cash, while grappling with questions about whether the growth is sustainable.

Bangkok Post

Why pregnant people were left behind while vaccines moved at ‘warp speed’ to help the masses

Kia Slade was seven months pregnant, unvaccinated, and fighting for breath, her oxygen levels plummeting, when her son came into the world last May.

Tribune News Service

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock

Moderna, Inc.

Benzinga

Will Moderna Be 'One Of The Most Valuable Healthcare Companies' In The World? Steve Weiss Believes So

Moderna Inc (NASDAQ: MRNA) is on the move Thursday following strong quarterly financial results. Short Hills Capital's Steve Weiss decided to pick up additional shares of the commercial-stage biotech company after the report.

Benzinga

Moderna Rallies After Earnings Print: Could A Technical Reversal Be In Sight?

Moderna Inc. (NASDAQ: MRNA) shares are trading after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

Stock Market Pares Losses After Russian Invasion; Nasdaq Escapes Most Of The Carnage

The stock market tumbled Thursday on Russia's invasion of Ukraine, but the tech-heavy Nasdaq escaped most of the carnage.

Investors Business Daily

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

Moderna Pops On Strong Covid Vaccine Sales, Though Offers Light Outlook

Moderna stock popped Thursday after sales of its Covid vaccine outperformed Wall Street's forecasts, though guidance for 2022 came in light.

Investors Business Daily

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna Inc (NASDAQ:MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion. Product sales were $6.9…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

COVID-19 vaccine sales push Moderna to $12B profit in 2021

Moderna’s COVID-19 vaccine brought in nearly $7 billion in the final quarter of 2021, and the drugmaker says it has signed purchase agreements for another $19 billion in sales this year

Benzinga

Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs

Moderna Inc (NASDAQ: MRNA) has en

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.

The Independent UK

WHO works to spread COVID vaccine technology to more nations

The World Health Organization is creating a global training center to help poorer countries make vaccines, antibodies and cancer treatments using the messenger RNA technology used to make COVID-19 vaccines

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Thinking About Buying Stock In Coinbase, Moderna Or Sunnova Energy?

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

The Conversation

The Moderna vaccine is now available for 6 to 11 year olds. Here's what parents need to know

Australian children aged six to 11 years old will be able to get the Moderna COVID vaccine at pharmacies, GP clinics and vaccination hubs from tomorrow.

ABC News

Moderna COVID-19 vaccine approved for six- to 11-year-old children

Children aged six to 11 years can get a Moderna COVID-19 vaccine from tomorrow, after it was given the final green light.

Investors Business Daily

Nine Beaten-Down Stocks Must Jump 100% Just To Get Your Money Back

If you're waiting for some fallen S&P 500 stocks to bounce back — hope you're patient. Many must double in value to get your money back.

The Conversation

Do COVID boosters cause more or fewer side effects? How quickly does protection wane? Your questions answered

The Australian Technical Advisory Group on Immunisation (ATAGI) recommends Australians aged 16 years and older have a COVID booster vaccine three months after receiving their second dose.

Benzinga

Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline

Moderna Inc (NASDAQ: MRNA) said it is deve

The Conversation

How trying to copy a COVID vaccine changes the outlook for African countries

The World Health Organisation (WHO) has announced the first six African countries that will receive technology to produce messenger RNA (mRNA) vaccines. This comes off the back of the news that a South African consortium – part of the WHO’s technology transfer hub set up in 2021– had successfully replicated…

1 … 33 34 35 36

People

Paul Offit

52 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Centers for Disease Control and Prevention

World Health Organisation

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.